Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer

Future Oncology · Published 2026-07-29 · DOI 10.1080/14796694.2026.2707796

Free full text

Authors (10)

Arun A. Azad, Bhavik J. Pandya, Hemant Singh Bhadauria, Erhan Berrak, Vagia Daki, Paulo Martins, Janet Kim, Alexis Serikoff, Gianluca Baio, Andrew J. Armstrong

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Azad, A., Pandya, B., Bhadauria, H., et al. (2026). Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. Future Oncology. https://doi.org/10.1080/14796694.2026.2707796

Related articles

• Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine · Expert Review of Anticancer Therapy · 2026 · Cites or is cited by this article
• Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · Future Oncology · 2026 · Same journal
• Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences · Future Oncology · 2026 · Same journal
• Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice · Future Oncology · 2026 · Same journal
• Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · Future Oncology · 2026 · Same journal
• Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience · Future Oncology · 2026 · Same journal
• IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · Future Oncology · 2026 · Same journal
• Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · Future Oncology · 2026 · Same journal
• Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions · Future Oncology · 2026 · Same journal
• A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer · Future Oncology · 2026 · Same journal